Furthermore, inhibiting CCL4 with a specific antibody has been found to attenuate systemic inflammation, improve insulin resistance, and reduce circulating insulin levels in both type 2 diabetes animal models and metabolic syndrome animal models (51). The gene discussed is INS; the disease is Insulin resistance.